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CLINICAL QUESTIONS
How effective is azathioprine at preventing recurrent flares
of Crohn’s disease among patients with quiescent disease?
When should a patient with Crohn’s disease start azathio-
prine?
CASE SCENARIO
An 18-yr-old woman presents with right lower quadrant ab-
dominal discomfort, unintentional 5-pound weight loss, and
intermittent diarrhea for the past 3 months. Initial evalu-
ation reveals mild normocytic anemia, elevated ESR, and
stool cultures with normal flora. Small bowel follow through
demonstrates a stricture of the distal 15 cm of the ileum.
Colonoscopy reveals inflammation in the terminal ileum and
biopsies are consistent with Crohn’s disease. The patient is
started on prednisone 40 mg daily and the dose is tapered
over 8 wk. Her symptoms resolve within 2 wk of starting
prednisone.
Recently, you read an article (1) which stated that the use
of immunosuppressant agents has increased in patients with
Crohn’s disease over the past 25 yr, and approximately 56%
of these patients used immunosuppressant agents in 1998–
2003 in Europe. During that period of 25 yr, intestinal re-
section for medical failure decreased, but intestinal resection
for stricturing and perforating complications did not change.
Approximately 50% of patients who underwent surgery never
received immunosuppressants and 30% did not receive im-
munosuppressant agents for more than 12 wk. Therefore, the
authors hypothesized that under-utilization of immunosup-
pressant agents prevented a reduction in intestinal surgery
for intestinal complications.
You wonder if azathioprine should be started in your
patient.
EBM APPROACH
A metaanalysis of six randomized controlled trials (RCT)
(n=319 total patients) compared azathioprine versus placebo
for prevention of recurrent flares in patients with quiescent
Crohn’s disease (2). Five of the six RCTs did not produce
a statistically significant result. In the metaanalysis, patients
using azathioprine were much more likely to stay in remission
compared to patients using placebo: OR = 2.27 (95% CI:
1.76–2.93). Overall, 67% (95% CI: 59–75%) of azathioprine-
treated patients remained in remission versus 53% (95% CI:
45–60%) of placebo-treated patients.
TERMINOLOGY
A systematic review is a review that utilizes explicit tech-
niques to systematically search, critically appraise, and syn-
thesize published studies that address a specific question. A
metaanalysis is a quantitative systematic review where statis-
tical techniques are used to combine the results from individ-
ual studies. Thus, proper performance of a metaanalysis re-
quires development of an appropriate question that identifies
specific patients, specific interventions, and a specific out-
come (e.g., among patients with quiescent Crohn’s disease,
is azathioprine more effective than placebo at maintaining
remission of Crohn’s disease). A comprehensive literature
search must be performed to identify all published studies
that address this question. Also, metaanalyses of treatments
usually limit the literature search to randomized trials, since
this design produces more accurate results as confounding
factors are reduced or removed (3). If these trials are also
“doubleblind”, then bias is also eliminated (3). A detailed
discussion of appropriate metaanalysis design may be found
in other texts (4).
Metaanalysis is most helpful when multiple small RCTs
suggest that a treatment is better than placebo, but most RCTs
do not produce statistically significant results. In this situa-
tion, the treatment may be better than placebo, but a signif-
icant result could not be demonstrated because of an insuf-
ficient sample size (i.e., an insufficient number of enrolled
patients). This is sometimes called a Type II error (3). In
a metaanalysis, the results from all RCTs are combined to
produce a summary result using a statistical technique. By
combining the results from all RCTs, a large number of pa-
tients are examined and a sufficient sample size is achieved.
This may seem like “magic”! How can you put the data
from multiple RCTs into a “black box,” which spits out a
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OR = 1.0OR = 0.01 OR = 100
Favors placebo Favors azathioprine
Test of Heterogeneity: p = 0.12
Odds Ratio= 2.27; 95% CI: 1.76-2.93
Figure 1. Azathioprine versus Placebo for quiescent Crohn’s dis-
ease.
summary result? For a valid metaanalysis, we rely on an im-
portant principle: if multiple RCTs examined the same types
of patients (patients with quiescent Crohn’s disease) with a
similar intervention (azathioprine vs placebo) and examined
a similar outcome (maintenance of remission of Crohn’s dis-
ease) and used a similar study design (RCT), then differences
between individual study results only occurred due to chance
and it is valid to combine the results from individual studies
into a metaanalysis. Figure 1 displays a Petogram, which is
the standard diagram for representing metaanalysis results.
There are six studies represented in this Petogram. For each
study, the vertical line represents the study result (expressed
as an odds ratio or OR) and the horizontal line represents
the 95% confidence intervals (95% CI). As you can see,
five of the six studies did not produce statistically significant
results: the horizontal lines (95% CI) from these studies cross
the center of the Petogram (OR = 1.0), which indicates a
nonstatistically significant result. At the bottom of Figure 1,
the summary result of the metaanalysis is provided: OR =
2.27; 95% CI: 1.76–2.93. Since a large number of patients
(n = 319) are included in the metaanalysis, a precise and
statistically significant estimate of the beneficial effects of
azathioprine is produced.
However, can we be sure that the individual studies used
similar patients, similar interventions, and measured similar
OR = 1.0OR = 0.01 OR = 100
Favors placebo Favors azathioprine
Test of Heterogeneity: p = 0.001
Odds Ratio= 2.27; 95% CI: 1.76-2.93
Figure 2. Hypothetical results for a metaanalysis with a highly sig-
nificant test of heterogeneity.
study outcomes? If the individual studies produced similar re-
sults, then this principle is probably fulfilled. We assess this
issue with the test of heterogeneity, which determines if the
differences between individual study results could have oc-
curred due to chance or if the differences between individual
study results are quite different and could not have occurred
due to chance. If there are statistically significant differences
between the results of individual studies, then the test of het-
erogeneity provides p < 0.10. In this situation, we assume
that the differences in results between individual studies oc-
curred because of important differences in study design, pa-
tient population, measurement of outcomes, etc. This concept
is demonstrated in Figure 2, which is a hypothetical example
of a metaanalysis that uses the widely divergent results from
multiple RCTs. Although this hypothetical metaanalysis pro-
duces a statistically significant summary result (OR = 2.27
with 95% CI: 1.76–2.93), this is not a valid metaanalysis be-
cause the test of heterogeneity provides a p-value = 0.001,
indicating that these studies are too different in study design
to combine into a metaanalysis.
If there are not statistically significant differences between
study results, then we assume that differences in individual
study results occurred due to chance and not because of im-
portant differences in study design. In this situation, the test
of heterogeneity produces a p-value >0.10 (Figure 1).
APPLICATION OF METAANALYSIS RESULTS AND TEST
OF HETEROGENEITY TO THE CLINICAL QUESTION
In the metaanalysis, patients with quiescent Crohn’s disease
were more likely to remain in remission compared to pa-
tients receiving placebo: OR = 2.27; 95% CI: 1.76–2.93.
The test of heterogeneity = 0.12, indicating that there are
not significant differences between the results of individ-
ual studies and that the differences in results of individual
studies probably occurred due to chance. Overall, 67% (95%
CI: 59–75%) of azathioprine-treated patients remained in re-
mission versus 53% (95% CI: 45–60%) of placebo-treated
patients.
APPLYING RESULTS TO YOUR PATIENT
In the metaanalysis by Pearson et al. (2), two of the RCTs
enrolled steroid-dependent Crohn’s disease patients, one trial
enrolled patients who had achieved remission on azathio-
prine, and three trials enrolled patients who were in remission
and had completed steroid tapers. Therefore, at least some of
the patients in this metaanalysis resemble your patient. How-
ever, approximately 9% of Crohn’s disease patients experi-
enced adverse events with use of immunosuppressive agents
significant enough to result in withdrawal from the study (2).
These adverse events included leukopenia, anemia, and pan-
creatitis (2). Patients using azathioprine get periodic checks
of their complete blood cell count and liver enzymes. Also,
there is a small but real risk of congenital anomalies among
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offspring of patients using azathioprine or 6-mercaptopurine
(5).
BOTTOM LINE
In practice, we would definitely start this patient on aza-
thioprine if she suffers a second flare of Crohn’s disease
in the next 12 months. Many of our colleagues would even
start azathioprine after the first course of prednisone or even
during the initial prednisone tapering period since azathio-
prine has also been shown to be effective at inducing re-
mission in active Crohn’s disease (2). Furthermore, an 18-
month randomized trial of 6-mercaptopurine versus placebo
in newly diagnosed pediatric patients with Crohn’s disease on
corticosteroids showed that mercaptopurine not only lowered
the duration and cumulative dose of corticosteroids required
to induce remission, it also lowered the risk of relapse af-
ter steroid-induced remission (6). Overall, we do think that
azathioprine is under-utilized in patients with Crohn’s dis-
ease due to safety concerns. Although these safety concerns
are real, the benefits of azathioprine outweigh the risks in
the majority of patients with Crohn’s disease. Although 5-
aminosalicylate agents are quite safe, we do not believe that
they are an effective alternative for maintenance of medi-
cally induced remission of ileocecal Crohn’s disease, and this
is borne out by a recently published Cochrane metaanalysis
(7).
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